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Abstract
Clinical evidence shows that circulating levels of adipocyte fatty-acid-binding protein (A-FABP) are elevated in
patients with diabetes and closely associated with ischaemic heart disease. Patients with diabetes are more
susceptible to myocardial ischaemia/reperfusion (MI/R) injury. The experiments in the present study investigated
the role of A-FABP in MI/R injury with or without diabetes. Non-diabetic and diabetic (streptozotocin-induced) A-FABP
knockout and wild-type mice were subjected to MI/R or sham intervention. After MI/R, A-FABP knockout mice
exhibited reductions in myocardial infarct size, apoptotic index, oxidative and nitrative stress, and inflammation.
These reductions were accompanied by an improved left ventricular function compared with the relative controls
under non-diabetic or diabetic conditions. After diabetes induction, A-FABP knockout mice exhibited a preserved
cardiac function compared with that in wild-type mice. Endothelial cells, but not cardiomyocytes, were identified as
the most likely source of cardiac A-FABP. Cardiac and circulating A-FABP levels were significantly increased in mice
with diabetes or MI/R. Diabetes-induced superoxide anion production was significantly elevated in wild-type mice,
but diminished in A-FABP knockout mice, and this elevation contributed to the exaggeration of MI/R-induced cardiac
injury. Phosphorylation of endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO) were enhanced
in both diabetic and non-diabetic A-FABP knockout mice after MI/R injury, but diminished in wild-type mice. The
beneficial effects of A-FABP deficiency on MI/R injury were abolished by the NOS inhibitor NG-nitro-L-arginine methyl
ester. Thus, A-FABP deficiency protects mice against MI/R-induced and/or diabetes-induced cardiac injury at least
partially through activation of the eNOS/NO pathway and reduction in superoxide anion production.
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INTRODUCTION
Ischaemic heart disease is one of the leading causes of death
worldwide [1]. The introduction of reperfusion therapy after acute
ischaemia limits infarct size, but may paradoxically cause addi-
Abbreviations: A-FABP, adipocyte fatty-acid-binding protein; AAR, area at risk; ApoE, apoliprotein E; AT, adipose tissue; DAPI, 4′,6-diamidino-2-phenylindole; DHE, dihydroethidium;
eNOS, endothelial nitric oxide synthase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H&E, haematoxylin and eosin; HRP, horseradish peroxidase; IL, interleukin; iNOS,
inducible nitric oxide synthase; KO, knockout; LAD, left anterior descending artery; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; LVESP, left ventricular end-systolic
pressure; MCP-1, monocyte chemoattractant protein-1; MI/R, myocardial ischaemia/reperfusion; L-NAME, NG-nitro-L-arginine methyl ester; PC, primary cardiomyocyte; qRT-PCR,
quantitative real-time PCR; ROS, reactive oxygen species; STZ, streptozotocin; THL, total heart lysate; TNF-α, tumour necrosis factor α; TTC, 2,3,5-triphenyltetrazolium chloride; TUNEL,
terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling; WT, wild-type.
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tional cardiac damage and complications, known as myocardial
ischaemia/reperfusion (MI/R) injury [2]. Diabetic patients are at
high risk of ischaemic heart disease [3] and are more susceptible
to MI/R injury, as evidenced by aggravated oxidative stress, car-
diomyocyte apoptosis and myocardial dysfunction [4]. However,
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the pathological link between diabetes andMI/R-induced cardiac
injury is unclear.
Adipocyte fatty-acid-binding protein (A-FABP), an adipokine
expressed in adipose tissues, activated macrophages as well as
endothelial cells, is a key mediator of obesity-related metabolic
deterioration and inflammation [5]. A-FABP can be released into
the circulation [6] and its serum levels are elevated in obese pa-
tients with either Type 1 or Type 2 diabetes [7,8], and is positively
associated with the key components of the metabolic syndrome,
including hyperlipidaemia, hyperglycaemia, hypertension [6] and
insulin resistance [7]. Both clinical and animal studies indicate
that A-FABP is a key player in the pathogenesis of endothelial
dysfunction and vascular diseases such as atherosclerosis [9].
Raised serum A-FABP levels are also closely associated with
ischaemic heart disease [10,11].
Clinical findings suggest that A-FABP is implicated in car-
diac dysfunction because raised serum A-FABP levels are asso-
ciated with left ventricular diastolic dysfunction [12] and cardiac
contractile dysfunction [13] in obese patients, or elevated left
ventricular mass and reduced myocardial performance index in
patients with obstructive sleep apnoea [14]. The circulating level
of A-FABP independently correlates with the severity of heart
failure in Chinese individuals [15] and is associated with in-
creased risk of heart failure in older patients in the U.S.A. [16].
However, whether A-FABP is involved in the development of
MI/R-induced cardiac dysfunction associated with diabetes re-
mains elusive.
Endothelial cell–cardiomyocyte interactions play a critical
role in the maintenance of cardiac function [17]. Endothelial cells
express and release autocrine and paracrine factors such as nitric
oxide (NO), endothelin-1, prostacyclin and angiotensin II, and
provide a constant oxygen and nutrient supply for the cardiomyo-
cytes [17]. Endothelial dysfunction in heart failure patients is as-
sociated with an elevated mortality [18]. In vitro studies suggest
that A-FABP is implicated in endothelial dysfunction. Indeed,
exogenous A-FABP suppresses endothelial nitric oxide synthase
(eNOS) phosphorylation by inhibiting insulin-induced insulin re-
ceptor substrate 1 (IRS-1) and Akt activity, which in turn reduces
NO production in endothelial cells [19,20]. By contrast, phar-
macological inhibition of A-FABP confers protection against en-
dothelial dysfunction in apolipoproteinE (ApoE) knockout (KO)
mice [19] and in the pig [21].
The present study aimed to investigate whether A-FABP plays
a pathophysiological role in MI/R-induced cardiac injury under
both non-diabetic and diabetic conditions.
EXPERIMENTAL
Generation of A-FABP-deficient mice
The A-FABP KO targeting vector was constructed from gen-
omic DNA fragments derived from a C57BL/6 genome, bac-
terial artificial chromosome clone. The targeting vector with a
3.5-kb 5′-upstream fragment from the ATG codon and a 5-kb
3′-downstream from the fourth exon of the A-FABP gene, encom-
passing luciferase and neomycin genes, was inserted into a pl253
vector. The linearized A-FABP KO targeting vector was elec-
troporated into the embryonic stem cells of 129SV/J mice. The
targeted clones were identified by PCR analysis and the A-FABP-
targeted embryonic stem cells weremicroinjected into blastocysts
and implanted into the uterus of C57BL/6Nmice to generate chi-
maeras that were backcrossed with C57BL/6N mice to generate
offspring. The genotypes of the pups were confirmed by PCR
analysis using specific primers for wild-type (WT) A-FABP or
A-FABP KO alleles (see Supplementary Table S1). A-FABP KO
mice were crossed into a C57BL/6N background for at least six
generations before the experiments. All mice were housed in a
temperature-controlled facility (23 ◦C) with a 12-h light/12-h–
dark cycle, and permitted free access to standard mouse chow
(Purina) and water. All experimental protocols were approved
by the Committee on the Use of Live Animals in Teaching and
Research at the University of Hong Kong.
Diabetes induction
Mice 8 weeks old were injected intraperitoneally with a low dose
(55 mg/kg) of streptozotocin (STZ, Alexa Biochemicals) dis-
solved in sterile 0.1 M citrate buffer for 5 consecutive days to
induce diabetes. Control mice were injected with citrate buf-
fer alone (pH 4.5). Mice with a blood glucose level higher than
300 mg/dl were considered to be diabetic. Blood glucose and
body weight were monitored once weekly.
MI/R protocol
As previous studies demonstrated that there are gender dif-
ferences in cardioprotection against global or myocardial
ischaemia/reperfusion, and showed that female rats or mice are
less susceptible than males to ischaemia/reperfusion injury [22],
the MI/R experiments were performed using male mice. Both
A-FABP KOmice and WT littermates were subjected to MI/R or
sham intervention after 8 weeks of diabetes induction. MI/R was
performed as described in [23]. In brief, age-matched WT and
A-FABP KO mice with similar body weight and glucose levels
were anaesthetized. Intratracheal intubation was performed to
provide artificial ventilation by connecting the tubing to a TOPO
Small Animal Ventilator (Kent Scientific) with a 0.3 ml tidal
volume, 120 breaths/min and a 10–12 cm H2O peak inspiratory
pressure. A left thoracotomy was performed, and the left anterior
descending artery (LAD) was ligated with an 8/0 silk suture. A
1-cm-long piece of polyethylene-10 tubing was placed on the
heart between the LAD and the suture to facilitate reperfusion.
The LAD was occluded completely for 30 min, and reperfused
for 2 or 24 h (for cardiac function determination). Sham-operated
control mice underwent the same surgical procedures, except that
the suture placed under the left coronary artery was not tied. To
study the effect of eNOS inhibition onMI/R- or diabetes-induced
cardiac dysfunction, subgroups of WT and A-FABP KO mice
were treated with the NOS inhibitor NG-nitro-L-arginine methyl
ester (L-NAME, Sigma–Aldrich) added to the drinking water at
1.5 mg/ml for 4 weeks.
Measurement of blood pressure
Systolic arterial blood pressure was determined non-invasively
by the tail-cuff method using BP-2000 Blood Pressure Analysis
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System (Visitech Systems) in conscious mice before they were
subjected to MI/R or determination of cardiac function, after a
training period of 5 days.
Determination of myocardial infarct size
At the end of reperfusion, the LAD was religated and 5% Evan’s
BlueDyewas injected directly into the left ventricle (LV) to delin-
eate the ischaemic from the non-ischaemic area. The heart was
then rapidly excised and cross-sectioned into 1-mm-thick sec-
tions, which were incubated with 1% 2,3,5-triphenyltetrazolium
chloride (TTC, Sigma–Aldrich) in 0.2 mol/l phosphate solution
for 20 min at 37 ◦C to identify viable tissue. The infarcted area
(unstained by TTC) and the area at risk (AAR, unstained by
Evan’s Blue Dye) were assessed using NIH Image J software.
The infarct area was expressed as a percentage of the AAR.
Determination of cardiac function
Cardiac function was determined by invasive ventricular cathet-
erization 24 h after reperfusion. A 1.4-Fr high-fidelity microtip
catheter connected to a pressure transducer (Millar Instruments)
was positioned into the LV through the right carotid artery to
record left ventricular pressure changes. The left ventricular end-
systolic pressure (LVESP), left ventricular end-diastolic pressure
(LVEDP), maximal rate of pressure development (dP/dtmax) and
maximal rate of decay of pressure (−dP/dtmin), representative of
cardiac systolic and diastolic performance, were obtained using
a PowerLab system (AD Instruments).
Determination of myocardial apoptosis
Myocardial apoptosis was detected by the terminal deoxynuc-
leotidyl transferase-mediated dUTP nick-end labelling (TUNEL)
assay using an In SituCell DeathDetectionKit (Roche) according
to the manufacturer’s instructions. The cardiac sections including
the entire MI/R areas were viewed at 488 nm excitation/512 nm
emission. TUNEL-positive nuclei were counted in 20 random
fields (×40) per animal and expressed as the percentage of total
nuclei.
Measurement of superoxide anion production
In situ levels of myocardial superoxide anions were determined
by dihydroethidium (DHE, Sigma–Aldrich) staining. DHE in-
tercalates into DNA on oxidization by intracellular superoxide
anions to produce fluorescent ethidium bromide. Frozen sections
of left ventricular tissue were incubated with 7.5 μM DHE at
37 ◦C for 30 min. Fluorescence images of ethidium bromide were
obtained using a fluorescence microscope (BX41 System micro-
scope; Olympus). The mean fluorescence intensities of DHE-
labelled positive myocyte nuclei were quantified in each of five
randomly selected fields and are shown as mean pixel intensity.
Determination of myocardial content of
nitrotyrosine and NO products
The nitrotyrosine content, an index of peroxynitrite formation
fromO2− andNO,was determined inMI/R tissue by chemilumin-
escent immunoassay using the competitive ELISA nitrotyrosine
assay kit (Millipore). The total concentration of NO products was
determined by quantification of two stable oxidized products of
NO, nitrites (NO2−) and nitrates (NO3−), using a nitrate/nitrite
colorimetric assay kit (Cayman Chemical) according to the man-
ufacturer’s instructions.
Immunohistochemistry and immunofluorescence
staining
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded (for A-FABP, troponin T and nitrotyrosine de-
tection) or frozen (for CD31 detection) left ventricular tissue sec-
tions. After deparaffinization and rehydration, the sections were
protected from endogenous peroxidases using 3% hydrogen per-
oxide for 30 min. Antigen retrieval was performed by incubating
the slides in sodium citrate buffer, pH 6.0, at 95 ◦C for 10 min.
The slides were incubated with primary antibody overnight at
4 ◦C in a humidity chamber, and the following primary antibod-
ies were used: mouse anti-nitrotyrosine (Rockland), goat anti-A-
FABP (R&D Systems) and mouse anti-troponin T (Thermo Sci-
entific) at a dilution of 1:100.On the following day, the slideswere
incubated with anti-goat or anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:500 dilution, Sigma–
Aldrich) at room temperature for 1 h, then developed with 3,3′-
diaminobenzidine (DAB) solution (Sigma–Aldrich) and counter-
stained for nuclei with haematoxylin solution. For immunofluor-
escence staining, monoclonal rat anti-CD31 (BD Bioscience) at
a dilution of 1:100 was also used (for frozen sections). Second-
ary antibodies were Alexa Fluor 594-conjugated chicken anti-
goat IgG, Alexa Fluor 488-conjugated chicken anti-goat IgG,
Alexa Fluor 594-conjugated rabbit anti-mouse IgG and Alexa
Fluor 488-conjugated chicken anti-rat IgG (Molecular Probes).
Primary antibody isotypes were used as negative controls. Nuclei
were stained with 4′,6-diamidino-2-phenylindole (DAPI, Invitro-
gen). Themean fluorescence intensities of positively stained cells
were quantified in each of five randomly selected fields.
Haematoxylin and eosin staining
Haematoxylin and eosin (H&E) staining was performed as de-
scribed in [24]. Heart tissues were fixed overnight in buffered
formaldehyde (10%) and embedded in paraffin. Sections that
were 5-μm-thick were prepared. The air-dried sections were
stained with H&E (Sigma–Aldrich) for histological analysis. The
images were obtained at ×400 magnification using a microscope
(BX41 System, Olympus) with a colour digital camera (Olympus
Model DP72).
Western blotting
Protein samples fromMI/R tissue homogenateswere separated by
SDS/PAGE, transferred onto PVDF membranes and probed with
primary antibodies against A-FABP (R&D Systems), phospho-
eNOS (Ser1177, BD Biosciences), eNOS (BD Biosciences), indu-
cible nitric oxide synthase (iNOS, Abcam) and β-actin (Cell Sig-
naling Technology). The membranes were then incubated with
HRP-conjugated secondary antibodies and developed with en-
hanced chemiluminescence reagents (GE Healthcare). The blot
densities were quantified using NIH ImageJ software.
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Quantitative real-time PCR
Total RNA was extracted from MI/R tissue using TRIzol re-
agent (Invitrogen). Total RNA (1 μg) was reverse-transcribed
into cDNA using Improm-II reverse transcription kit (Promega).
Quantitative real-time (qRT-PCR) was performed using SYBR
Green Reagent (Qiagen) on an ABI Prism 7000 sequence de-
tection system (Applied Biosystems). The primer sequences of
inflammation-related genes used for reverse transcription–PCR,
including tumour necrosis factor α (TNF-α), monocyte chemoat-
tractant protein-1 (MCP-1), interleukin-6 (IL-6) and F4/80, are
listed in Supplementary Table S2. The level of target gene
expression was analysed using the 2(−C
T ) method and nor-
malized against the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene.
Biochemical analysis
Blood glucose was measured using an ACCU-Chek glucose
meter (Roche). Serum A-FABP levels were measured using a
mouse A-FABP ELISA kit (BioVendor Laboratory Medicine).
Statistical analysis
All data in the present study are expressed as means+−S.E.M.
Data that were not normally distributed, as determined by the
Kolmogorov–Smirnov test, were transformed logarithmically to
produce normally distributed data before analysis. Statistically
significant differences between groups were determined using
one-way ANOVA analysis followed by Bonferroni’s post-hoc test
with SPSS version 16.0. Two-sided values of P< 0.05 were con-
sidered to indicate statistically significant differences.
RESULTS
Generation of systemic A-FABP KO mice
A-FABP KO mice were generated using a gene-targeting ap-
proach with a vector replacing exons 1–4 of the A-FABP gene
with luciferase and neomycin genes (see Supplementary Figure
S1a). Genotyping analysis using gene-specific primers was per-
formed to identify the WT, A-FABP KO and heterozygous mice
(see Supplementary Figure S1b). The absence of A-FABP protein
expression in the heart of A-FABP KO mice was confirmed by
immunoblotting and immunohistochemistry staining using goat
anti A-FABP antibodies (see Supplementary Figures S1c and
S1d).
A-FABP deficiency protects against MI/R-induced
cardiac injury in both non-diabetic and diabetic
mice
WT and A-FABPKOmice with STZ-induced diabetes developed
rapid and persistent hyperglycaemia throughout the experimental
period, which was accompanied by a markedly reduced body
weight (see Supplementary Figure S2). No significant differences
in body weight and blood glucose were found between WT and
A-FABP KO mice in either the diabetic or the control groups.
MI/R resulted in significant myocardial infarction in both
WT and A-FABP KO mice, which was exacerbated by dia-
betes. In both normal and diabetic mice, the percentage of the
infarct area in the AARwas significantly reduced in A-FABP KO
mice compared with their respective WT controls (non-diabetic
WT: 47.64+− 2.48%; non-diabetic KO: 29.20+− 1.86%; diabetic
WT: 56.67+− 2.62%; diabetic KO: 43.75+− 2.15%; P< 0.01)
(Figure 1a). The extent of apoptosis in the AAR regions was
determined by TUNEL staining. Consistent with the results of
infarct size measurement, MI/R induced significant cardiac cell
apoptosis, as indicated by the increased TUNEL positive-stained
nuclei in WT and A-FABP KO mice compared with sham con-
trols. MI/R-induced apoptosis was more severe in both types of
mice under diabetic conditions (inWTmice: non-diabetic 54.4%
compared with diabetic 72.6%, P= 0.001; in A-FABP KOmice:
non-diabetic 35.1% compared with diabetic 45.2%, P= 0.013).
A-FABP KO mice exhibited a significantly lower proportion of
TUNEL-positive cells in their myocardium compared with their
WT controls in both the non-diabetic and the diabetic groups
(both P< 0.01) (Figure 1b), suggesting that A-FABP deficiency
protects mice against MI/R-induced cardiac damage irrespective
of the presence of diabetes.
A-FABP deficiency protects against diabetes- or
MI/R-induced cardiac dysfunction
Severe hyperglycaemia was paralleled by impairment of both
cardiac contractile and diastolic functions in WT mice, whereas
diabetic A-FABP KO mice had a preserved cardiac function
(Figures 2a–2d). MI/R induced significant cardiac systolic dys-
function as evidenced by reductions in LVESP (Figure 2a: in
non-diabetic WT mice: sham 85.93+− 2.06 mmHg compared
with MI/R 55.18+− 1.14 mmHg, P< 0.001; in non-diabetic
KO mice: sham 84.51+− 1.22 mmHg compared with MI/R
67.93+− 2.41 mmHg, P= 0.002) and dP/dtmax (Figure 2c; in
non-diabetic WT mice: sham 4561.60+− 62.29 mmHg/s com-
pared with MI/R 2877.65+− 46.77 mmHg/s, P< 0.001; in non-
diabetic KO mice: sham 4562.67+− 195.81 mmHg/s compared
with MI/R 3616.30+− 87.88 mmHg/s, P= 0.023) in both WT
and A-FABP KO mice, whereas the reductions were con-
sistently less in A-FABP KO mice. Diabetes further ex-
acerbated the MI/R-induced cardiac systolic dysfunction in
both types of mice (in WT mice, LVESP reduced from
55.18+− 1.14 to 42.09+− 1.52 mmHg; in A-FABP KO mice, from
67.93+− 2.41 to 54.67+− 0.69 mmHg; dP/dtmax reduced from
2877.65+− 46.77 to 1578.54+− 88.33 mmHg/s in WT mice, and
from 3616.30+− 162.74 to 2945.27+− 99.60 mmHg/s in A-FABP
KO mice; all P< 0.05) (Figures 2a and 2c). MI/R induced a sim-
ilar increment of LVEDP and reduction in −dP/dtmin in both WT
and KO mice whereas diabetes further exaggerated the MI/R-
induced impairment of cardiac diastolic function only in WT (all
P< 0.05), but not in A-FABP KO mice (Figures 2b and 2d).
A-FABP deficiency attenuates MI/R- and
diabetes-induced myocardial oxidative and nitrative
stresses and inflammation
MI/R injury alone caused a severe disruption of the geometric
alignment of cardiomyocytes in WT mice although the effect
on A-FABP KO mice was mild. Diabetes alone also slightly
altered the alignment of cardiomyocytes in WT mice but not in
A-FABPKOmice.Under diabetic conditions,MI/R injury caused
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Figure 1 A-FABP deficiency attenuates myocardial infarction and apoptosis in MI/R-induced mice with (DM) or without
(non-DM) diabetes
A-FABP-KO mice and their WT littermates were subjected to either vehicle (citrate buffer) or STZ injection to induce
Type 1 diabetes followed by MI/R injury. (a) Myocardial infarct size was determined by Evan’s Blue/TTC double staining.
Upper panel: representative photomicrographs of heart sections obtained from MI/R-induced WT and A-FABP KO mice
with or without DM. The blue-staining areas indicate normal myocardium, red-staining areas represent ischaemic but
non-infarcted tissue, and unstained white areas indicate infarcted tissue. Lower panel: quantification of myocardial infarct
size expressed as percentage of AAR, calculated as ischaemic area plus infarcted area divided by total area of the
heart. (b) Diabetes- and MI/R-induced cardiac cell apoptosis was determined by TUNEL staining of the heart sections.
TUNEL-stained apoptotic nuclei green and total nuclei were counterstained blue with DAPI. Magnification ×40. Values are
expressed as means +− S.E.M. ∗P< 0.05, ∗∗P< 0.01; n= 5–6.
amarked reduction in the number of cardiomyocytes inWTmice,
as indicated by the reduced number of stained nuclei, whereas
MI/R injury and diabetes induction had no synergistic effect on
cardiac structural changes in A-FABP KO mice (Figure 3a).
The production of superoxide anion and formation of per-
oxynitrite were next accessed in cardiac tissue. DHE staining
indicated that MI/R- or diabetes-induced superoxide anion pro-
duction was significantly reduced in A-FABPKOmice compared
with WT mice (Figure 3b). MI/R and diabetes synergistically in-
creased superoxide anion production in both types of mice, but
A-FABP KOmice consistently showed a significantly lower level
when compared with WT mice (39–49% reduction in ethidium
fluorescence intensity in KO mice compared with WT mice un-
der MI/R, diabetes or diabetes+MI/R conditions). In addition,
MI/R injury significantly increased nitrotyrosine formation in
WT, but not in A-FABP KO, mice. Although diabetes alone did
not increase nitrotyrosine formation in both types of mice, dia-
betes significantly exaggeratedMI/R-induced nitrotyrosine form-
ation in WT mice, although that in A-FABP-deficient hearts
was significantly attenuated as indicated by immunohistological
staining (Figure 3c) and chemiluminescent protein quantification
(Figure 3d).
Furthermore, MI/R induced a significant increase in cardiac
expression of inflammatory cytokines, including TNF-α, MCP-
1 and IL-6 in WT mice, whereas only the expression of MCP-1
was significantly enhanced in A-FABPKOmice, when compared
with their respective sham control. Moreover, the MI/R-induced
increase in inflammatory cytokines was significantly attenuated
in the KO mice when compared with the respective WT mice (in
WT mice, 3.37+− 0.24-fold, 10.83+− 1.30-fold and 8.17+− 0.37-
fold increased, respectively, compared with in A-FABP KO
mice, 2.08+− 0.12-fold, 4.99+− 0.41-fold and 1.25+− 0.13-fold
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Figure 2 A-FABP deficiency attenuates cardiac dysfunction caused by diabetes induction or MI/R in mice with (DM) or
without (non-DM) diabetes
Cardiac systolic and diastolic functions were determined by left ventricular catheterization as indicated by (a) LVESP,
(b) LVEDP, (c) dP/dtmax and (d) −dP/dtmin. Values are expressed as means +− S.E.M. ∗P< 0.05, ∗∗P< 0.01; n= 5–6.
increased, respectively) (Figure 3e). Diabetes alone did not in-
duce the cardiac expression of any inflammatory cytokine in
both WT and A-FABP KO mice, but it significantly enhanced
the MI/R-induced expression of TNF-α and IL-6 inWTmice, al-
though the effect on that in A-FABP-KO mice was markedly
diminished (Figure 3e). There was no significant increase in
the cardiac mRNA expression level of F4/80 in the hearts of
both WT and A-FABP KO mice after MI/R and/or diabetes in-
duction, and the levels of F4/80 were similar between the two
types of mice (see Supplementary Figure S3), suggesting that
no significant macrophage infiltration had occurred. These data
are consistent with previous findings that infiltration of macro-
phages starts at day 3 in the MI/R model [25]. Taken together,
these results suggest that A-FABP deficiency attenuates MI/R-
induced and/or diabetes-induced cardiac injury, at least par-
tially, by reducing myocardial oxidative and nitrative stresses and
inflammation.
The endothelium is the major cell source of cardiac
A-FABP and its expression is induced further by
MI/R and diabetes
Immunofluorescence staining demonstrated that A-FABP is ex-
pressed abundantly in the heart of WT mice (see Supplement-
ary Figure S4a). Co-immunofluorescence staining showed that
A-FABP co-localized only with the endothelial marker CD31,
not with the cardiomyocyte marker troponin T (Figure 4a), sug-
gesting that the major cell source of cardiac A-FABP is the en-
dothelium.Western blot analysis also demonstrated that A-FABP
was detected in adipose tissue (AT) and total heart lysate (THL)
but not in primary cardiomyocytes (PCs) (Figure 4b). The mRNA
expression of A-FABP in PCs was also undetectable by qRT-PCR
(Figure 4c).
MI/R or diabetes caused a significant up-regulation of mRNA
expression (Figure 4d) and protein presence (Figure 4e) of A-
FABP in the heart tissue of WT mice. In addition, diabetes in-
duced a higher expression of A-FABP than MI/R injury. Under
diabetic conditions, MI/R further induced a mild but insignificant
increase inmRNA and protein expression of cardiac A-FABP and
its circulating level (see Supplementary Figure S4b). These data
suggest that the elevated expression of A-FABP in diabetic mice
subjected to MI/R is contributed to mainly by diabetes induction
rather than MI/R injury. The cardiac expression of A-FABP was
significantly higher in diabetic mice with MI/R compared with
non-diabetic mice withMI/R (Figures 4d and 4e). A similar trend
was observed for the serum A-FABP levels (see Supplementary
Figure S4b), in line with previous clinical findings demonstrating
raised circulating A-FABP levels in patients with diabetes [7,8]
and/or ischaemic heart disease [10,11].
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Figure 3 A-FABP deficiency alleviates MI/R- and diabetes-induced cardiac histological change, oxidative and nitrative
stress, and inflammation
(a) Histological analysis of heart sections by H&E staining. (b) Cardiac superoxide anion production was determined by in
situ DHE staining. The fluorescence of DHE-labelled positive nuclei (red) was calculated in each of five randomly selected
fields and was expressed as mean pixel intensity. (c) Immunohistochemistry staining of cardiac nitrotyrosine in each of five
randomly selected fields. Magnification ×40. (d) Myocardial nitrotyrosine content was determined by chemiluminescence.
(e) The mRNA abundance of pro-inflammatory cytokines TNF-α, MCP-1 and IL-6 in heart tissues was determined by qRT-PCR
and normalized to the GAPDH gene. DM, diabetes mellitus. Values are expressed as means +− S.E.M. ∗P< 0.05, ∗∗P< 0.01;
n= 5–6.
A-FABP deficiency enhances eNOS phosphorylation
and NO production in the MI/R heart
The eNOS/NO pathway exerts cardioprotective effects against
apoptosis and oxidative stress [26]. Exogenous A-FABP inhib-
its eNOS activation and NO production in cultured endothelial
cells [20]. As A-FABP is expressed in cardiac endothelial cells
and its expression is up-regulated by MI/R and diabetes, the
next experiments examined whether A-FABP deficiency exerts
its cardioprotective effect by modulating the eNOS/NO path-
way. In WT mice, MI/R caused a significant down-regulation
of eNOS phosphorylation, and this detrimental effect was fur-
ther exacerbated in diabetic mice, whereas diabetes alone did
not alter eNOS phosphorylation (Figure 5a). By contrast, dia-
betes alone or MI/R injury induced a significant and similar in-
crease in eNOS phosphorylation in A-FABP-deficient hearts, but
MI/R injury did not further enhance eNOS phosphorylation in
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Figure 4 Endothelial cells are the major cell source of cardiac A-FABP, and its expression is further induced by MI/R and
diabetes
(a) Co-immunofluorescence staining of cardiac A-FABP with the endothelial cell marker CD31 and the cardiomyocyte marker
troponin T in the heart sections of WT mice. (b) Western blot analysis of A-FABP expression and (c) the mRNA abundance
of A-FABP in AT, THL and PCs of WT mice. (d) The mRNA abundance of cardiac A-FABP in MI/R- and/or diabetes-induced WT
mice was determined by qRT-PCR. (e) Immunofluorescence staining of cardiac A-FABP of MI/R- and/or diabetes-induced
WT mice. Right panel: quantification of the fluorescence intensity. DM, diabetes mellitus. Values are expressed as
means +− S.E.M. ∗P< 0.05, ∗∗P< 0.01; n= 6.
heart tissue of diabetic A-FABP KO mice (Figure 5b). Consist-
ent with the increased eNOS phosphorylation, MI/R-subjected
A-FABP-deficient hearts showed a significantly enhanced total
NO production compared with those of WT controls under
either control or diabetic conditions (Figure 5c, 1.60+− 0.14 com-
pared with 0.92+− 0.16 nmol/μg under non-diabetic conditions,
P= 0.015; 1.90+− 0.13 compared with 0.91+− 0.07 nmol/μg un-
der diabetic conditions, P= 0.005). However, diabetic A-FABP
KO mice exhibited only a slightly higher NO production when
compared with the respective WT mice (1.20+− 0.08 compared
with 0.78+− 0.07 nmol/μg, P= 0.05) (Figure 5c). These data sug-
gest that activation of the eNOS/NO pathway onMI/R or diabetes
induction was suppressed in the presence of A-FABP. To determ-
ine whether the beneficial effect of A-FABP deficiency on MI/R
injury is attributable to the increased NO production, WT and
A-FABP KO mice were pre-treated with either vehicle or the
NOS inhibitor, L-NAME 1.5 mg/ml, followed by either diabetes
induction or MI/R injury. The systolic arterial blood pressure of
both WT and A-FABP KO mice was significantly increased to
a similar extent after treatment with L-NAME, whereas diabetes
induction with STZ did not affect arterial blood pressure in either
type ofmouse.Moreover, STZdid not further increase the systolic
blood pressure of L-NAME-treated mice (see Supplementary
Figure S5). Furthermore, the present data also show that treat-
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Figure 5 A-FABP deficiency protects against MI/R-induced car-
diac injury through activation of the eNOS/NO pathway
Western blots measuring eNOS phosphorylation (Ser1177) in heart tis-
sues of (a) WT and (b) A-FABP KO mice. t-eNOS, total eNOS. (c) Cardiac
NO production of A-FABP KO mice and WT mice. DM, diabetes mellitus.
Values were expressed as means +− S.E.M.s. ∗P< 0.05, ∗∗P< 0.01;
n= 6.
ment with L-NAME did not alter the MI/R- or diabetes-induced
cardiac injury and function in WT mice (Figure 6). On the con-
trary, the beneficial effects of A-FABP deficiency on the allevi-
ation of MI/R-induced myocardial infarction and deterioration of
cardiac function were attenuated significantly when the A-FABP
KO mice were treated with L-NAME (Figures 6a and 6b). How-
Figure 6 Treatment of NOS inhibitor abolishes the cardioprotect-
ive effects of A-FABP KO mice on MI/R injury
A-FABP KO mice and their WT littermates were treated with either vehicle
(Veh) or L-NAME for 4 weeks, followed by MI/R injury or after diabetes
induction. Effects of eNOS inhibition on MI/R-induced (a) myocardial
infarction and (b) cardiac dysfunction. (c) Effect of eNOS inhibition on
diabetes-induced cardiac dysfunction in A-FABP KO and WT mice. DM,
diabetes mellitus. Values are expressed as means +− S.E.M. ∗P< 0.05,∗∗P< 0.01; n= 6.
ever, NOS inhibition did not exaggerate diabetes-induced cardiac
systolic dysfunction in A-FABP KOmice (Figure 6c). These data
suggest that A-FABP deficiency protects against MI/R-induced
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cardiac injury mainly because of increased NO production. How-
ever, increased NO production in the A-FABP-deficient heart
did not contribute to the alleviation of diabetes-induced cardiac
dysfunction.
To exclude other molecular sources that could be responsible
forMI/R-induced increased NO production in A-FABPKOmice,
the protein expression of iNOS was also determined. There was
no significant change in iNOS expression afterMI/R in eitherWT
or A-FABP KO animals (see Supplementary Figure S6) which
suggests that the elevated NO production in A-FABP KO mice
mainly depends on eNOS activity.
DISCUSSION
A-FABP is recognized as a key mediator of various obesity-
related cardiometabolic disorders [5]. Clinical and in vitro stud-
ies suggest that A-FABP is also implicated in cardiac dysfunc-
tion [12–15]. A-FABP-deficient mice are protected against diet-
induced metabolic disorders such as insulin resistance, hyperlip-
idaemia and fatty liver despite their increased susceptibility to
diet-induced obesity compared with WT mice [28]. Therefore,
in the present study, a STZ-induced Type 1, rather than a diet-
induced Type 2, diabetes model was established to investigate the
role of A-FABP in MI/R-induced cardiac injury associated with
the disease, and to minimize the metabolic discrepancy between
WT and A-FABP KO mice on diabetes induction, which may
affect MI/R injury.
The data in the present study show that endothelial cells were
identified as themajor cellular source of cardiacA-FABP,which is
supported by our previous findings [19]. Both mRNA and protein
expression of A-FABP were markedly increased in the cardiac
tissues of STZ-exposed and/or MI/R-subjected mice, and the
former exhibited a higher A-FABP expression than the latter. This
induction of cardiac A-FABP was accompanied by an elevated
circulating level of the adipokine. Under diabetic conditions,
MI/R can only slightly but insignificantly enhance the expression
of A-FABP in mice. This may be due to the severe induction of
A-FABP expression by STZ-induced diabetes which masked the
additive effect of MI/R.
A-FABP deficiency conferred cardioprotection with dimin-
ished infarct size and reduced cardiac apoptosis, and maintained
better cardiac systolic and diastolic functions on MI/R-induced
cardiac injury under both non-diabetic and diabetic conditions.
The induction of NO production in A-FABP-deficient heart is
specific for MI/R injury but not for diabetes induction. Moreover,
treatment with the NOS inhibitor L-NAME attenuates the bene-
ficial effect of A-FABP deficiency in alleviating MI/R-induced
myocardial infarction and cardiac dysfunction, but not those in-
duced by diabetes, although it exerts no effect on WT mice.
These data suggest that the cardioprotective effect of A-FABP
deficiency on MI/R injury is at least in part due to activation of
the eNOS/NO pathway in endothelial cells, which subsequently
alleviates cardiac oxidative stress and inflammation. Moreover,
A-FABP deficiency protects against diabetes-induced cardiac
dysfunction by attenuating superoxide anion production. Under
diabetic conditions, the presence of elevated superoxide anion
further exaggerates MI/R-induced oxidative and nitrative stress
and inflammation, leading to more severe cardiac damage and
impairment of cardiac function. Thus, the findings of the present
study provide in vivo evidence that A-FABP is involved in the
development of MI/R- or diabetes-induced cardiac injury and
dysfunction, as well as the exaggeration of MI/R-induced car-
diac injury under diabetic condition. Consistent with previous
findings [3,4], the data from the present study show that diabetes
increases the susceptibility to MI/R-induced cardiac injury and
that this can probably be attributed to the markedly enhanced
expression of A-FABP.
Cardiomyocyte survival depends on capillary endothelial cells
for a proper supply of oxygenated blood, and the expression
and release of protective signals and a variety of autocrine and
paracrine factors to maintain cardiac metabolism, growth and
an appropriate coronary vascular diameter [17]. Endothelial dys-
function precedes most cardiovascular diseases and is implic-
ated in cardiac dysfunction [18]. The bioavailability of NO syn-
thesized from L-arginine by eNOS plays an obligatory role in
the maintenance of proper endothelial function [29]. Patients
with diabetes exhibit a reduced ability to generate NO from L-
arginine [30] and are more susceptible to ischaemia/reperfusion
injury compared with healthy controls [4]. Mice deficient in
eNOS also show increased MI/R injury [31]. Conversely, genetic
over-expression of eNOS or NO donors attenuate MI/R injury
in mice [32,33]. The eNOS/NO pathway exerts various cardi-
ovascular protective effects through the suppression of oxidative
stress, inflammation and apoptosis [26]. Consistent with these
findings, the present observation of elevated eNOS phosphoryla-
tion and increased NO production in the heart of A-FABP KO
mice explains the protective effects of the deletion against MI/R
injury.
Exogenous A-FABP and lipid-induced A-FABP expression
decrease eNOS phosphorylation and NO production in cultured
endothelial cells whereas pharmacological inhibition of A-FABP
reverses the condition and improves endothelial function in ApoE
KO mice [19,20] and prevents coronary endothelial dysfunction
in the pig [21]. The findings of the present study demonstrate
that A-FABP is expressed in cardiac endothelial cells but not in
cardiomyocytes, and that this expression increases in response
to acute MI/R injury and diabetes; this suggests that its adverse
effect on endothelial cells contributes to cardiac dysfunction.
Cardiac eNOS phosphorylation and NO production after MI/R
were significantly reduced inWTmice, but both were augmented
in A-FABP KO mice, an increase associated with reduced car-
diac apoptosis and improved function. These data imply that a
protective mechanism associated with the activation of eNOS in
response to MI/R is suppressed in the presence of A-FABP, with
a resultant decreased NO bioavailability, illustrating the develop-
ment of endothelial dysfunction. This interpretation is helped by
the observation that the beneficial effects of A-FABP deficiency
were abolished by the administration of the eNOS inhibitor L-
NAME.
Although eNOS can also be expressed in cardiomyocytes, the
endothelium is themajor contributor of eNOS-derivedNO affect-
ing myocardial contractility [34]. In the isolated rabbit heart, the
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increase in myocardial NO production in response to mechanical
stimulation is abrogated after removing cardiac endothelial and
endocardial cells [35]. Furthermore, the inotropic response of
cardiac ventricular myocytes to β-adrenergic stimulation neces-
sitates the production of NO from the coronary microvascular en-
dothelium [34,36]. These findings also support the interpretation
that MI/R-induced cardiac dysfunction can be primarily attrib-
uted to the endothelial dysfunction caused by A-FABP-mediated
alterations in the eNOS/NO pathway.
Endothelial dysfunction resulting from an impaired
eNOS/NO pathway increases oxidative stress and inflammation,
which further enhance the severity of the endothelial dysfunction.
This vicious cycle and the additive effects eventually contribute
to heart failure [29]. Elevated production of reactive oxygen spe-
cies (ROS) on MI/R injury directly damages lipids, proteins and
DNA, resulting in irreversible oxidative modifications [37] as-
sociated with increased apoptosis, cardiac hypertrophy and con-
tractile dysfunction [38]. Elevated ROS also cause mitochondrial
uncoupling, leading to cellular energy depletion in the diabetic
heart [39]. ROS can interact with NO to generate nitrotyrosine,
leading to severe nitrative stress and additional cardiac dam-
age [40]. Superoxide anions scavenge NO and thus reduce NO
bioavailability, contributing to endothelial dysfunction and ap-
optosis [41]. Hyperglycaemia-induced oxidative stress also en-
hances cardiac inflammation by activating the pro-inflammatory
c-Jun N-terminal kinase (JNK) signalling pathway [42]. The res-
ults of the present study show that A-FABP KO mice exhibited
an attenuated MI/R- and/or diabetes-induced cardiac ROS pro-
duction. Reduced oxidative stress diminished nitrative stress in
both the absence and the presence of diabetes, which may con-
tribute to the subsequent alleviation of cardiac cell apoptosis and
inflammation.
Pro-inflammatory cytokines also critically contribute to the
pathogenesis of MI/R-induced injury. Elevated TNF-α and IL-6
promote cardiac hypertrophy, fibrosis and left ventricular dys-
function [43,44]. TNF-α and IL-1β increase epicardial thickness
and induce cardiac contractile dysfunction [45]. A-FABP is a
key mediator of inflammatory responses in macrophages [46,47]
whereas both genetic disruption and pharmacological inhibition
of A-FABP result in decreased production of pro-inflammatory
cytokines [5]. However, in the present study, no macrophage in-
filtration was evidenced in the myocardium after acute MI/R in-
jury and/or diabetes induction in eitherWT or A-FABPKOmice,
and the cardiac expression of the macrophage marker F4/80 was
also similar, suggesting that the attenuated cardiac inflammation
in A-FABP KO mice after MI/R can be attributed mainly to the
anti-inflammatory role of NO, the diminished ROS production
in the myocardium on MI/R and diabetes induction, or the low
systemic inflammatory state in A-FABP KO mice. The elevated
expression of inflammatory cytokines in response to myocardial
infarction may be contributed by cardiac fibroblasts and car-
diomyocytes [48,49]. Exposure to cytokines is associated with
induction of iNOS expression and activity mainly in infiltrated
inflammatory cells [50]. However, there was no change in iNOS
expression among groups in the present study, which may be due
to a non-significant macrophage infiltration in the myocardium
on short-term MI/R injury.
In conclusion, the present study provides the novel insight that
A-FABP plays a critical role in the development of acute MI/R-
induced cardiac dysfunction by inducing oxidative stress and in-
flammation primarily via the modulation of the eNOS/NO path-
way in endothelial cells. Diabetes-induced elevation of A-FABP
associated with raised superoxide anion production may account
for its adverse effect on the exaggeration of MI/R-induced in-
jury. These findings highlight the importance of A-FABP in the
pathogenesis of cardiac disorders. In particular, they suggest that
A-FABP may be a potential therapeutic target for the treatment
of diabetes-associated cardiac complications.
CLINICAL PERSPECTIVES
 Circulating levels of A-FABP are elevated in patients with
diabetes and closely associated with ischaemic heart disease,
but the pathological link between diabetes and MI/R-induced
cardiac injury remains unclear. The present study was de-
signed to investigate the role of A-FABP in MI/R injury under
non-diabetic and diabetic condition.
 Endothelial expression of A-FABP is increased on diabetes
induction and acute MI/R. Elevated A-FABP expression
plays a critical role in the development of acute MI/R in-
jury by suppressing eNOS activation and NO production.
Diabetes-induced elevation of A-FABP expression, associ-
ated with increased superoxide anion production, may con-
tribute to the diabetes-induced cardiac dysfunction and the
further exaggeration that it causes of MI/R-induced cardiac
injury.
 A-FABP is a negative regulator of the eNOS/NO path-
way causing endothelial dysfunction, which subsequently
contributes to cardiac dysfunction by inducing oxidative
stress and inflammation. A-FABP may be a potential thera-
peutic target for the treatment of diabetes-associated cardiac
diseases.
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